Formycon Surpasses 2023 Forecast with Stellar Performance - Preliminary Results Out Now

• Group revenue increased by 83% to €77.7 million compared to the previous year
• Positive Group EBITDA of around €1.5 million achieved
• New key financial performance indicator "Adjusted Group EBITDA" amounts to €13.3 million
• Group net result stood at €75.8 million due to a one-off, non-cash adjustment
• Cash and cash equivalents increased to €27.0 million
• 2024 guidance reflects a year of transition and investment in a sustainable biosimilar pipeline

The next important date, Publication of consolidated/annual financial statements, at Formycon is on 25.04.2024.

The price of Formycon at the time of the news was 48,00EUR and was up +3,39 % compared with the previous day.

Formycon

+2,94 %

+6,13 %

-11,18 %

-16,68 %

-41,20 %

-38,38 %

+15,77 %

+505,03 %

+364,25 %

ISIN:DE000A1EWVY8WKN:A1EWVY

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max